Literature DB >> 31992580

Characterisation of heterozygous PMS2 variants in French patients with Lynch syndrome.

Qing Wang1, Julie Leclerc2, Gaëlle Bougeard3, Sylviane Olschwang4, Stéphanie Vasseur3, Kévin Cassinari3, Denis Boidin5, Cédrick Lefol6, Pierre Naïbo6, Thierry Frébourg3, Marie Pierre Buisine2, Stéphanie Baert-Desurmont3.   

Abstract

BACKGROUND: Heterozygous germline PMS2 variants are responsible for about 5% of Lynch syndrome (LS) but their prevalence is most likely underestimated because of complicated routine screening caused by highly homologous pseudogenes. Consequently, there is limited knowledge on the implication of the PMS2 gene in LS.
METHODS: We report 200 PMS2 heterozygous variants identified in 195 French patients, including 112 unique variants classified as class-3/4/5.
RESULTS: Genomic rearrangements account for 18% of alterations. The c.137G>T variant was observed in 18% of the patients, but a founder effect could not be clearly identified by haplotype analysis. Among class-4/5 variant carriers, the median age at first tumour onset was 49 years with a predominance of colorectal (80%) and endometrial (8.1%) cancers. Seven patients developed colorectal cancers before the age of 30 with the youngest at the age of 21. Only 6.2% of class-4/5 carriers had a family history fulfilling Amsterdam I/II criteria among patients with available data. Tumours from PMS2 variant carriers exhibited microsatellite instability (96%) and loss of PMS2 expression (76%), confirming the high predictive value of somatic analysis.
CONCLUSION: Our results provide further insight into the role of the PMS2 gene in LS. While PMS2 variants are mostly detected in families not fulfilling Amsterdam criteria, which supports their lower penetrance, they can nevertheless cause early-onset cancers, highlighting the variability of their penetrance. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Lynch syndrome; MMR deficiency; PMS2; cancer predisposition; germline variant

Mesh:

Substances:

Year:  2020        PMID: 31992580     DOI: 10.1136/jmedgenet-2019-106256

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  4 in total

1.  Detecting inversions in routine molecular diagnosis in MMR genes.

Authors:  Edwige Kasper; Sophie Coutant; Sandrine Manase; Stéphanie Vasseur; Pierre Macquère; Gaëlle Bougeard; Laurence Faivre; Olivier Ingster; Stéphanie Baert-Desurmont; Claude Houdayer
Journal:  Fam Cancer       Date:  2022-01-08       Impact factor: 2.375

2.  An unusual phenotype occurs in 15% of mismatch repair-deficient tumors and is associated with non-colorectal cancers and genetic syndromes.

Authors:  Marion Jaffrelot; Nadim Farés; Rosine Guimbaud; Janick Selves; Anne Cécile Brunac; Anne Pascale Laurenty; Marie Danjoux; David Grand; Samira Icher; Julie Meilleroux; Eliane Mery; Etienne Buscail; Charlotte Maulat; Christine Toulas; Pierre Vande Perre; Edith Chipoulet; Delphine Bonnet; Anne Staub
Journal:  Mod Pathol       Date:  2021-09-20       Impact factor: 7.842

Review 3.  Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors.

Authors:  Julie Leclerc; Catherine Vermaut; Marie-Pierre Buisine
Journal:  Cancers (Basel)       Date:  2021-01-26       Impact factor: 6.639

4.  Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2.

Authors:  Mythili Merchant; Margarita Raygada; Ying Pang; Martha Quezado; Mark Raffeld; Liqiang Xi; Jung Kim; Manoj Tyagi; Zied Abdullaev; Olga Kim; Zach Sergi; Tina Pillai; Byram Ozer; Kareem Zaghloul; John D Heiss; Terri S Armstrong; Mark R Gilbert; Kenneth Aldape; Jing Wu
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.